Media headlines about Cascadian Therapeutics (NASDAQ:CASC) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cascadian Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.7577357483595 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
CASC has been the topic of a number of research analyst reports. Cowen and Company restated a “buy” rating on shares of Cascadian Therapeutics in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Monday, July 17th. Cantor Fitzgerald restated a “hold” rating and set a $4.00 price objective on shares of Cascadian Therapeutics in a report on Thursday, August 31st. ValuEngine lowered shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, Barclays PLC initiated coverage on shares of Cascadian Therapeutics in a report on Wednesday, September 6th. They set an “underweight” rating and a $4.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Cascadian Therapeutics has a consensus rating of “Hold” and a consensus price target of $5.63.
Shares of Cascadian Therapeutics (NASDAQ:CASC) opened at 4.28 on Friday. The firm has a 50-day moving average of $3.91 and a 200 day moving average of $3.94. The firm’s market capitalization is $216.37 million. Cascadian Therapeutics has a 52 week low of $3.18 and a 52 week high of $8.82.
Cascadian Therapeutics (NASDAQ:CASC) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.06. During the same quarter in the prior year, the business earned ($1.57) EPS. On average, equities analysts predict that Cascadian Therapeutics will post $5.02 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/10/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-cascadian-therapeutics-casc-stock-price.html.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.